Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine hydrochloride dry suspension plus basic therapy in children with chronic allergic rhinitis and asthma
ChiCTR2600131268Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fexofenadine in allergic rhinitis (AR) and asthma (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Total Nasal Symptom Score and asthma control rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
fexofenadine
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on ChiCTR2600131268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131268.